Barchart Demo Center

Overview

Stocks

Stock Screeners

ETFs

Futures

Funds

Fund Screeners

Foreign Exchange

Sectors

News

Financial Calculators

Embedded Widgets

Portfolio

Screener

JSON Feeds

Symbol Overview

United States|Canada
English|French

Intellia Thera CS

(NASDAQ: NTLA)
Add to Portfolio
-0.81 (-6.37%)
as of Apr 7, 2020

Last 11.90
Change -0.81 (-6.37%)
Open 13.03
Prev. Close 12.71
Today's Range
11.86
13.09
52wk Range
9.18
19.00
Volume 740898
Avg Volume 783145
Sector SIC-2835 In Vitro & In Vivo Diagnostic Substances

Perfomance Comparison

Name Today 3-Month 1-Year
NTLA -6.37% -11.52% -35.36%
DJIA -0.12% -20.61% -14.27%
S&P 500 -0.16% -18.01% -8.07%

Key Statistics

Annual EPS -2.11
Dividend Yield 0.00%
P/E Ratio N/A
Market Capitalization, $K 586100
Weighted Alpha -32.45
Standard Deviation -0.72
Profit Margin N/A
Beta 1.78

Growth Rates

YTD -18.88%
1-Year -25.37%
3-Year -8.69%

Opinion

Sell Hold Buy

Recent Headlines

FDA Accepts Investigational New Drug Application for

GlobeNewswire via COMTEX - Tue Mar 31, 07:30AM EDT
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, announced that the U.S. Food and Drug Administration (F(full story)
NVS: 83.99 (-1.74), NTLA: 11.90 (-0.81)

Intellia Therapeutics to Participate at June

GlobeNewswire via COMTEX - Thu May 30, 04:30PM EDT
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will participate in the following upcoming healthcare c(full story)
NTLA: 11.90 (-0.81)

Intellia Therapeutics Names Laura Sepp-Lorenzino,

GlobeNewswire via COMTEX - Tue May 28, 07:50AM EDT
Intellia Therapeutics, Inc., (NASDAQ:NTLA) has named Laura Sepp-Lorenzino, Ph.D., as its new executive vice president and chief scientific officer. Dr. Sepp-Lorenzino brings decades of leadership and research and development exper(full story)
NTLA: 11.90 (-0.81)

New Research: Key Drivers of Growth for Pier 1

GlobeNewswire via COMTEX - Mon May 06, 08:45AM EDT
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Pier 1 Imports, Inc. (NYSE:PIR), American Woodmark Co(full story)
PIR: 3.56 (-0.22), AMWD: 47.27 (+1.31), KIRK: 0.7200 (+0.0123), NTLA: 11.90 (-0.81)

Intellia Therapeutics Announces First Quarter 2019

GlobeNewswire via COMTEX - Thu May 02, 07:30AM EDT
-- Remains on track to submit investigational new drug application in 2020 for its first systemically delivered CRISPR/Cas9-based therapy, NTLA-2001, for treatment of transthyretin amyloidosis(full story)
NTLA: 11.90 (-0.81)